TB-500
Thymosin Beta-4 Synthetic Analog
What is TB-500?
TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein expressed in virtually all human and animal cells. Tβ4 is a critical regulator of actin polymerization — the process by which cells form their internal scaffolding and enable movement, division, and repair.
The key functional region of Thymosin Beta-4 is a short actin-binding segment (LKKTETQ), and TB-500 is specifically designed around this domain. This makes TB-500 a targeted version of the full protein, with the portion believed responsible for the majority of its tissue repair effects.
TB-500 promotes cell migration, differentiation, and angiogenesis — making it useful in preclinical research on wound healing, muscle repair, cardiac tissue regeneration, and inflammation reduction. Unlike BPC-157, which is gut-derived, TB-500 is a skeletal and cardiac repair-focused compound.
Research Evidence
Tβ4 (the parent compound) has completed Phase II clinical trials showing accelerated healing of diabetic foot ulcers and pressure ulcers. TB-500 as a synthetic analog extrapolates these findings; direct human trials for TB-500 specifically are limited.
Strong preclinical data in rodent models showing Tβ4 promotes cardiac progenitor cell activation and reduces infarct size post-MI. Thymosin Beta-4 has entered clinical cardiac trials separately.
Animal models show improved healing of muscle tears and ligament injuries. Mechanism consistent with actin regulation and VEGF upregulation.
Tβ4 modulates NF-κB signaling, reducing inflammatory cytokine production in several preclinical models. Effect in the synthetic TB-500 analog is assumed but not directly confirmed in all models.
Evidence grades: Gold = RCT human data · Silver = multiple animal studies or parent compound human data · Bronze = limited or preliminary
Dosing Protocols
Reconstitution
TB-500 is supplied as a lyophilized powder. Reconstitute with bacteriostatic water. Common vial sizes are 2 mg and 5 mg.
| Vial | BAC Water | Concentration | 2 mg draw |
|---|---|---|---|
| 2 mg | 1 ml | 2,000 mcg/ml | 100 units (1.0 ml) |
| 5 mg | 2.5 ml | 2,000 mcg/ml | 100 units (1.0 ml) |
| 5 mg | 5 ml | 1,000 mcg/ml | 200 units (2.0 ml) |
Frequently Asked Questions
What is TB-500?
TB-500 is a synthetic analog of Thymosin Beta-4, a naturally occurring protein involved in actin regulation, tissue repair, and cell migration. It is researched for wound healing, injury recovery, inflammation reduction, and cardiac repair.
What is the TB-500 dosing protocol?
Common protocols use a loading phase of 2–2.5 mg twice weekly for 4–6 weeks, followed by maintenance of 2–2.5 mg every 2 weeks. Some combine TB-500 with BPC-157 for synergistic injury repair.
Is TB-500 legal in 2026?
TB-500 is currently FDA Category 2, meaning it cannot be compounded by licensed 503A pharmacies. The FDA PCAC is reviewing TB-500 on July 23, 2026 for potential Category 1 reclassification.
How does TB-500 differ from BPC-157?
BPC-157 is a gut-derived peptide with strong GI and tendon healing effects. TB-500 is derived from Thymosin Beta-4 and works primarily through actin regulation and cardiac/skeletal muscle repair. They are often stacked together for comprehensive injury recovery (the Wolverine Stack).
This profile was prepared using AI-assisted research synthesis. Citations are provided where applicable — verify with primary sources before clinical application.